The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

More than 40% of non-small cell lung cancer (NSCLC) patients lack actionable targets and require non-targeted chemotherapeutics. Many become refractory to drugs due to underlying resistance-associated mutations. KEAP1 mutant NSCLCs further activate NRF2 and upregulate its client PTGR1. LP-184, a nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Aditya, McDermott, Joseph Ryan, Kathad, Umesh, Modali, Rama, Richard, Jean-Philippe, Sharma, Panna, Bhatia, Kishor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057270/
https://www.ncbi.nlm.nih.gov/pubmed/33889302
http://dx.doi.org/10.18632/oncotarget.27943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057270/
https://www.ncbi.nlm.nih.gov/pubmed/33889302
http://dx.doi.org/10.18632/oncotarget.27943

Ejemplares similares